147 related articles for article (PubMed ID: 15179666)
21. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
[TBL] [Abstract][Full Text] [Related]
22. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
23. The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro.
Melkersson K; Jansson E
Neuro Endocrinol Lett; 2005 Jun; 26(3):205-8. PubMed ID: 15990722
[TBL] [Abstract][Full Text] [Related]
24. [Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].
Rubio G; Gómez-de-la-Cámara A; Ledesma F; Burón JA; Rodríguez-Morales A; Martínez-Junquera G;
Med Clin (Barc); 2006 Apr; 126(12):441-4. PubMed ID: 16620729
[TBL] [Abstract][Full Text] [Related]
25. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
26. New-onset diabetes and ketoacidosis with atypical antipsychotics.
Wilson DR; D'Souza L; Sarkar N; Newton M; Hammond C
Schizophr Res; 2003 Jan; 59(1):1-6. PubMed ID: 12413635
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
29. Atypical antipsychotics: newer options for mania and maintenance therapy.
Vieta E; Goikolea JM
Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
[TBL] [Abstract][Full Text] [Related]
30. [Schizophrenia, diabetes mellitus and antipsychotics].
Gury C
Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
[TBL] [Abstract][Full Text] [Related]
31. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
32. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
[TBL] [Abstract][Full Text] [Related]
33. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.
Ramaswamy K; Masand PS; Nasrallah HA
Ann Clin Psychiatry; 2006; 18(3):183-94. PubMed ID: 16923657
[TBL] [Abstract][Full Text] [Related]
34. Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone).
Martínez Martínez L; Olivera Fernández MR; Piñeiro Corrales G
Farm Hosp; 2009; 33(4):224-8. PubMed ID: 19712611
[TBL] [Abstract][Full Text] [Related]
35. Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Auclair AL; Kleven MS; Barret-Grévoz C; Barreto M; Newman-Tancredi A; Depoortère R
Behav Brain Res; 2009 Nov; 203(2):288-95. PubMed ID: 19464324
[TBL] [Abstract][Full Text] [Related]
36. Comparative safety of antipsychotics: another look at the risk of diabetes.
Moisan J; Turgeon M; Desjardins O; Grégoire JP
Can J Psychiatry; 2013 Apr; 58(4):218-24. PubMed ID: 23547645
[TBL] [Abstract][Full Text] [Related]
37. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
38. Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.
Filaković P; Koić O; Laufer D; Radanović-Grgurić L; Degmecić D; Pozgain I
Coll Antropol; 2007 Dec; 31(4):1105-9. PubMed ID: 18217467
[TBL] [Abstract][Full Text] [Related]
39. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
40. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
Feldman PD; Hay LK; Deberdt W; Kennedy JS; Hutchins DS; Hay DP; Hardy TA; Hoffmann VP; Hornbuckle K; Breier A
J Am Med Dir Assoc; 2004; 5(1):38-46. PubMed ID: 14706127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]